Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 7, 2010, Pages 3146-3151

  Sun, Xiaoping ^a   Barlow, Elizabeth A ^a   Ma, Shidong ^a   Hagemeier, Stacy R ^a   Duellman, Sarah J ^a   Burgess, Richard R ^a   Tellam, Judy ^b   Khanna, Rajiv ^b   Kenney, Shannon C ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

17 AAG; 17 DMAG; Epstein Barr virus; Geldanamycin; Translation

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; EPSTEIN BARR VIRUS ANTIGEN; GELDANAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOMA; VIRUS GENOME;

ANIMALS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; DIPEPTIDES; DNA PRIMERS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, SCID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4; MUS;

EID: 77649261204     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910717107     Document Type: Article

References (37)

1. Kieff E, Richinson AB (2007) Epstein-Barr virus and its replication. Fields' virology (Lippincott Williams & Wilkins, Philadelphia), 5th ed. eds Knipe D, etal., pp 2603-2654.
2. Niller HH, Wolf H, Minarovits J (2008) Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 41: 298-328.
3. Lindner SE, Sugden B (2007) The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 58:1-12.
4. Kapoor P, Lavoie BD, Frappier L (2005) EBP2 plays a key role in Epstein-Barr virus mitotic segregation and is regulated by aurora family kinases. Mol Cell Biol 25: 4934-4945.
5. Wu H, Ceccarelli DF, Frappier L (2000) The DNA segregation mechanism of Epstein-Barr virus nuclear antigen 1. EMBO Rep 1:140-144.
6. Altmann M, et al. (2006) Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci USA 103: 14188-14193.
7. Kennedy G, Komano J, Sugden B (2003) Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 100:14269-14274.
8. Saridakis V, et al. (2005) Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 18:25-36.
9. Neckers L, Neckers K (2002) Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 7:277-288.
10. Grenert JP, et al. (1997) Theamino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem272:23843-23850.
11. Prodromou C, et al. (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65-75.
12. Dai C, Whitesell L (2005) HSP90: a rising star on the horizon of anticancer targets. Future Oncol 1:529-540.
13. Kamal A, et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410.
14. Daskalogianni C, et al. (2008) Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing. J Biol Chem 283:30090-30100.
15. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 94:12616-12621.
16. Tellam J, et al. (2007) Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J Exp Med 204:525-532.
17. Tellam J, et al. (2008) Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci USA 105: 9319-9324.
18. Yin Y,Manoury B, Fåhraeus R (2003) Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301:1371-1374.
19. Nomura N, Nomura M, Newcomb EW, Zagzag D (2007) Geldanamycin induces G2 arrest in U87MG glioblastoma cells through downregulation of Cdc2 and cyclin B1. Biochem Pharmacol 73:1528-1536.
20. Tellam J, et al. (2004) Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 199:1421-1431.
21. Paludan C, et al. (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593-596.
22. Qing G, Yan P, Xiao G (2006) Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK). Cell Res 16:895-901.
23. Yates JL, Warren N, Sugden B (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313:812-815.
24. Fuller W, Cuthbert AW (2000) Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes delta F508 CFTR in the rabbit reticulocyte lysate. J Biol Chem 275:37462-37468.
25. Cameron JE, et al. (2008) Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology 382:257-266.
26. Kang MS, Hung SC, Kieff E (2001) Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci USA 98:15233-15238.
27. Zou P, Kawada J, Pesnicak L, Cohen JI (2007) Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 81:10029-10036.
28. Kim TS, et al. (2006) Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation. Mol Biol Cell 17:824-833.
29. Robles AI, et al. (2006) Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res 12:6547-6556.
30. Lam N, Sandberg ML, Sugden B (2004) High physiological levels of LMP1 result in phosphorylation of eIF2 alpha in Epstein-Barr virus-infected cells. J Virol 78:1657-1664.
31. Geller R, Vignuzzi M, Andino R, Frydman J (2007) Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 21:195-205.
32. Chase G, et al. (2008) Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 377:431-439.
33. BashaW, et al. (2005) Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus. Antivir Chem Chemother 16:135-146.
34. Burch AD, Weller SK (2005) Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J Virol 79: 10740-10749.
35. Yin Q, Flemington EK (2006) siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346:385-393.
36. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and nononcogene addiction. Cell 136:823-837.
37. Sitki-Green D, Covington M, Raab-Traub N (2003) Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. J Virol 77: 1840-1847.